The departure of business adviser Robert Whelan from the board of directors at Ariad Pharmaceuticals last week is fueling speculation that CEO and co-founder Harvey Berger may soon be under pressure to step down from the struggling cancer biotech firm.
Whelan’s resignation from Ariad’s (Nasdaq: ARIA) 10-member board of directors effective Oct. 1 was revealed in a federal filing last week. He served on the board since 2010, and a replacement has not yet been named.
Help employers find you! Check out all the jobs and post your resume.
